

Panion recruits new board

Panion has now completed recruitment of a new board and management to lead development of a business strategy for Panion.

Members have been chosen to ensure a diversity of expertise and experience from many areas of business development, veterinary medicine and regulatory strategy.

The new board consists of chairman Lars Thunberg, MSc and co-founder of CombiGene; Dede Willis, specialist in start-ups, strategic planning, acquisitions and product development; Nerry Kamstrup, experienced specialist veterinarian, and Lars Friis Mikkelsen, specialist in preclinical and clinical animal studies and veterinary pharmacology development.

The board members look forward to developing and marketing new medicines for animals, particularly for diseases and disorders for which there are currently no good treatment alternatives.

Read board and management biographies here:
panion-animalhealth.com/managementboard/

The company in brief

In June 2015 CombiGene formed a wholly owned subsidiary, then called CombiGene Vet AB, and in April 2016 the decision was taken to distribute the subsidiary to CombiGene's shareholders with the aim of listing the company. The company, which has been renamed Panion Animal Health AB, will use CombiGene's discoveries to develop a treatment for canine epilepsy. Panion Panion aims at inlicensing or acquiring other veterinary medicine projects or products.

Panion Animal Health AB

Medicon Village, SE-223 81 Lund, Sweden
info@panion-animalhealth.com

linkedin.com/company/panion-animalhealth 
twitter.com/panionanihealth 
panion-animalhealth.com/newsletter 
panion-animalhealth.com 